Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$63.08 USD
-0.35 (-0.54%)
Updated Apr 22, 2024 11:56 AM ET
After-Market: $64.43 +1.36 (2.15%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Viking Therapeutics, Inc. (VKTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$114.22 | $138.00 | $90.00 | 80.10% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Viking Therapeutics, Inc. comes to $114.22. The forecasts range from a low of $90.00 to a high of $138.00. The average price target represents an increase of 80.1% from the last closing price of $63.42.
Analyst Price Targets (9 )
Broker Rating
Viking Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.10 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.10 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 90% and 10% of all recommendations. A month ago, Strong Buy made up 90%, while Buy represented 10%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.10 | 1.10 | 1.10 | 1.11 | 1.11 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/15/2024 | BTIG | Justin R Zelin | Strong Buy | Strong Buy |
3/8/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/1/2024 | Maxim Group | Naz Rahman | Strong Buy | Strong Buy |
2/29/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
2/27/2024 | Raymond James | Steven Seedhouse | Moderate Buy | Moderate Buy |
2/23/2024 | William Blair | Andy T Hsieh | Strong Buy | Strong Buy |
10/25/2023 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.10 |
ABR (Last week) | 1.10 |
# of Recs in ABR | 10 |
Average Target Price | $114.22 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -0.27 |